Ditchcarbon
  • Contact
  1. Organizations
  2. Ipsen Biopharmaceuticals, Inc.
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated 18 days ago

Ipsen Biopharmaceuticals, Inc. Sustainability Profile

Company website

Ipsen Biopharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States and operates extensively across North America and Europe. Founded in 1929, Ipsen has established itself as a leader in the development of innovative therapies, particularly in oncology, neuroscience, and rare diseases. The company is renowned for its core products, including Somatuline® and Dysport®, which are distinguished by their unique formulations and targeted delivery mechanisms. Ipsen's commitment to research and development has led to significant milestones, including the expansion of its product portfolio and strategic partnerships that enhance its market position. With a focus on patient-centric solutions, Ipsen continues to achieve notable recognition within the biopharmaceutical sector, driving advancements that improve patient outcomes globally.

DitchCarbon Score

How does Ipsen Biopharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

83

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

31

Industry Benchmark

Ipsen Biopharmaceuticals, Inc.'s score of 83 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.

89%

Let us know if this data was useful to you

Ipsen Biopharmaceuticals, Inc.'s reported carbon emissions

Inherited from Ipsen S.A.

Ipsen Biopharmaceuticals, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Ipsen S.A., which cascades its climate commitments and emissions data. As part of its parent organisation's initiatives, Ipsen Biopharmaceuticals is aligned with various climate strategies, including those from the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both sourced from Ipsen S.A. at a cascade level of 2. While specific reduction targets or achievements for Ipsen Biopharmaceuticals are not detailed, the overarching commitments from Ipsen S.A. indicate a focus on sustainability and climate action. The company is involved in industry-standard initiatives aimed at reducing carbon footprints and enhancing environmental responsibility. As a subsidiary, Ipsen Biopharmaceuticals is expected to adhere to the climate strategies set forth by its parent company, reflecting a commitment to addressing climate change and reducing greenhouse gas emissions in line with global standards.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20192021202220232024
Scope 1
14,316,000
00,000,000
00,000,000
00,000,000
0,000,000
Scope 2
4,343,000
0,000,000
0,000,000
000,000
000,000
Scope 3
121,718,000
00,000,000
00,000,000
-
00,000,000

How Carbon Intensive is Ipsen Biopharmaceuticals, Inc.'s Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Ipsen Biopharmaceuticals, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Ipsen Biopharmaceuticals, Inc.'s Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Ipsen Biopharmaceuticals, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Ipsen Biopharmaceuticals, Inc.'s Scope 3 Categories Breakdown

Ipsen Biopharmaceuticals, Inc.'s Scope 3 emissions, which increased by 405% last year and decreased by approximately 25% since 2019, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 67% of Scope 3 emissions.

Top Scope 3 Categories

2024
Purchased Goods and Services
67%
Capital Goods
8%
Business Travel
8%
Upstream Transportation & Distribution
6%
Fuel and Energy Related Activities
4%
Employee Commuting
3%
Waste Generated in Operations
3%
Upstream Leased Assets
<1%
Downstream Transportation & Distribution
<1%
End-of-Life Treatment of Sold Products
<1%

Ipsen Biopharmaceuticals, Inc.'s Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Ipsen Biopharmaceuticals, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Ipsen Biopharmaceuticals, Inc.'s Emissions with Industry Peers

Vertex Pharmaceuticals

US
•
Pharmaceutical Preparation Manufacturing
Updated 9 days ago

Spectrum Pharmaceuticals, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 27 days ago

Forma Therapeutics Holdings, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 17 days ago

Merz Pharmaceuticals, LLC

US
•
Pharmaceutical Preparation Manufacturing
Updated about 2 months ago

Merck And Co

US
•
Pharmaceutical Preparation Manufacturing
Updated about 2 hours ago

Celgene Corporation

US
•
Pharmaceutical Preparation Manufacturing
Updated 20 days ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251030.3
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy